NewsRoom Articles - Page 2 of 131

FridayJan 20, 2023 10:47 am

Stem Cell Therapy Holds Promise in Future Cancer Care

Cancer is the second leading cause of death in the United States after heart disease, accounting for an estimated 602,350 deaths in 2020 and 608,570 deaths in 2021. Although we still don’t know exactly what causes normal cells to become cancerous, scientists have narrowed down several risk factors and developed various treatments to prolong the lives of cancer patients. These treatments include surgery, radiation, and chemotherapy or immunotherapy; these treatments are usually meant to rid the patient’s body of cancer cells. We know that the cancer develops when something goes wrong during the cell division process where damaged cells and…

ThursdayJan 19, 2023 11:58 am

New Research Suggests HRT May Reduce Alzheimer’s Risk in Women

Women make up nearly two-thirds of the people who suffer from Alzheimer’s in the United States. They account for almost 4 million of the more than 6 million patients aged 65 and over who live with Alzheimer's in the country; they also have a one-in-five risk of developing the neurological condition at 65. Researchers from Alzheimer’s Research UK have now discovered that hormone replacement therapy (HRT) may be able to lower women’s risk of developing Alzheimer’s in their lifetimes. Past studies have determined that a gene called APOE4 may increase an individual’s risk of Alzheimer’s disease. In this new observational…

ThursdayJan 19, 2023 9:00 am

MetAlert, Inc. (MLRT) Signs Letter of Intent to Acquire TrakTec on Synergistic and Complementary Technologies Set to Offer Short and Long-Term Benefits

MetAlert recently signed a Letter of Intent to acquire Florida-based TrakTec in a cash and stock deal worth $4.5 million TrakTec manufactures and sells affordable location awareness technology solutions for consumer, enterprise, and government applications The planned acquisitions will bring on board synergistic and complementary technologies that fit in with MetAlert’s subscription model and existing suite of location-sensitive and tracking solutions The acquisition is also set to offer both short- and long-term benefits, eventually contributing to the company’s efforts to up-list MetAlert (OTC: MLRT), a pioneer in location-sensitive wearable technology products and human and health monitoring devices, is looking to…

WednesdayJan 18, 2023 10:55 am

Study Finds Early Retirement May Worsen Cognitive Decline

A new study carried out by researchers at Binghamton University has found that retiring at an early age may speed up cognitive decline among the elderly. Assistant economics professor Plamen Nikolov led the study, with the help of economics doctoral student Shahadath Hossain. The researchers’ objective was to determine how retirement plans affected cognitive performance. They focused on Asia, which has recorded a decline in fertility and has a higher life expectancy, meaning the elderly make up the biggest demographic. This has created a need for better sustainable pension systems. For their study, the duo examined data obtained from the…

TuesdayJan 17, 2023 12:21 pm

Scientists Discover Unknown T Cell Function That Can Help Fight Fungal Infections

New research has found that some T cells secrete cytokines that may help fight against fungal infections and autoimmune illnesses. T cells are a type of white blood cell that help protect the body against infection. Different T cells have different functions in helping fight infection. T helper cells, for example, secrete cytokines that attract other immune cells to the infection site. These cells can also counteract inflammation. The new study, led by Professor Christina Zielinski of the Friedrich Schiller University, discovered a cytokine in Th17 cells that was proinflammatory. Cytokines are small proteins that play an important role in…

TuesdayJan 17, 2023 12:00 pm

India Globalization Capital Inc. (NYSE American: IGC) Announces Beginning of Phase 2 Clinical Trials for Proprietary Drug Candidate in Treating Alzheimer’s

Believed to be the first natural low-doses of THC-based compound to enter human trials for Alzheimer’s IGC-AD1 has the potential to revolutionize the treatment of Alzheimer’s disease The clinical trial is expected to produce data to “help us to further understand the metabolism of IGC-AD1 for a diverse population,” says CEO In a historic first, India Globalization Capital (NYSE American: IGC) has begun Phase 2 clinical trials evaluating its flagship drug candidate, IGC-AD1, for the treatment of agitation in dementia from Alzheimer’s disease (https://nnw.fm/Y1rLN). Company officials noted that, to their knowledge, this is the first natural low-dose THC-based compound to…

TuesdayJan 17, 2023 10:30 am

BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) Preclinical Study on Inhaled NanoAb COVID-19 Therapy Shows Elimination of Virus from Lungs

BiondVax is developing a pipeline of nanosized antibody (“NanoAb”) therapies addressing diseases with large underserved medical needs and attractive commercial opportunities BiondVax recently announced results from a preclinical in vivo proof-of-concept study indicating its innovative inhaled NanoAb COVID-19 therapy virtually eliminates viral presence in the lungs and leads to significantly shorter and milder illness BiondVax CEO Amir Reichman presented at the Biotech Showcase Conference, where he discussed recent successful results from the preclinical in vivo study, additional pipeline plans for other NanoAb therapeutics, and the company’s derisked R&D strategy Mainland China is experiencing a fresh wave of COVID-19 infections sweeping…

FridayJan 13, 2023 10:53 am

Researchers Design a New Way to Kill Cancer Using Cancer Cells

Researchers at Brigham and Women’s Hospital may have found another way to treat cancer; the new approach involves transforming cancer cells into anti-cancer agents. The researchers developed the new therapy approach, which can train the immune system to prevent the disease from recurring while also eliminating primary tumors. Dr. Khalid Shah, the study’s corresponding author, stated that the group’s objective was to turn cancer cells into cancer vaccines and killers. He explained that the scientists repurposed cancer cells using gene engineering to design a therapy that eliminated tumor cells and stimulated the immune system to prevent cancer and destroy established…

FridayJan 13, 2023 9:45 am

Wearable Tracking Device Developer MetAlert, Inc. (MLRT) Set to Build on 2022’s Progress to Uplist, Expand Medical Data Offerings

MetAlert recently released its yearend shareholder update letter, covering the past year’s progress, and associated plans for 2023, all focused on helping to monitor the safety and location of dementia patients and other vulnerable individuals Coupled with concerns about patients with Alzheimer’s disease or other brain conditions that may lead toward risks of them wandering, becoming lost or disoriented, or falling, the situation demonstrates an opportunity for remote monitoring of patients’ whereabouts To meet the need, MetAlert developed a pioneering wearable GPS-enabled tracking device a decade ago that unobtrusively slips into wearers’ shoes The company has since expanded the device’s…

ThursdayJan 12, 2023 11:44 am

Study Finds Pharmacotyping Pediatric Leukemia Offers Blueprint to Better Precision Medicine

Researchers at St. Jude’s Children Research Hospital have conducted a new study looking into drug sensitivity among patients with acute lymphoblastic leukemia across a variety of genetic subtypes. Acute lymphoblastic leukemia is a common childhood cancer that affects white blood cells. It is estimated that roughly 98% of children suffering from this cancer type will experience remission after a few weeks of treatment. Of this number, almost 90% will be cured. Current treatments for acute lymphoblastic leukemia are risk adapted, which means that chemotherapy is based on leukemia genomics, clinical features and the extent of minimal residual disease. The researchers’…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050